News Releases
Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
May 12, 2022
Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Mar 30, 2022
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Progress
Mar 09, 2022
Prometheus Biosciences to Participate at the Cowen 42nd Annual Healthcare Conference
Mar 01, 2022
Prometheus Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
Feb 07, 2022
Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference
Jan 12, 2022
Prometheus Biosciences to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
Jan 05, 2022
Prometheus Biosciences and Dr. Falk Pharma Advance PR600 and Trigger Final Preclinical Milestone Payment
Jan 03, 2022
Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Dec 07, 2021
Prometheus Biosciences Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Progress
Nov 12, 2021
Displaying 1 - 10 of 34